Skip to content

Studying coagulation specific for COVID-19 using "Blood-vessel-on-chip" technology.

Studying coagulation specific for COVID-19 using "Blood-vessel-on-chip" technology.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON27363
Enrollment
24
Registered
2021-01-11
Start date
2021-01-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Blood taking procedure (total amount of 22.1 mL blood)

Sponsors

ZonMw
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Age of 18 years or older - A suspected SARS-CoV-2 virus infection - Need for oxygen supplementation - CRP level > 50 mg/L - D-dimer level > 0.5 mg/L - Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: - History of venous thromboembolism - Use of anticoagulant therapy at inclusion - Known hereditary or acquired thrombophilia

Design outcomes

Primary

MeasureTime frame
Percentage of endothelial surface in the blood-vessel-on-chip model that is covered by platelets and fibirn ("clotting") upon treatment with COVID-19 patient plasma. Coverage in the blood-vessel-on-chip will be measured by fluorescence microscopy.

Secondary

MeasureTime frame
Several measurements in the patient plasma: - d-dimer level - thrombin-antithrombin complexes (TAT) - cytokine levels ((IL-1ß, IL-6, and TNF-a) - Markers of neutrophil extracellular traps (NETs) using ELISA: a) Myeloperoxidase (MPO)/DNA b) Citrullinated histone H3 - Tissue factor (TF) expressing extracellular vesicles as measured by a TF-dependent factor Xa activity assay.

Contacts

Public ContactThijs van Haaps

Amsterdam UMC loc. AMC

t.f.vanhaaps@amsterdamumc.nl020-5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)